Literature DB >> 7397479

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

C Confavreux, G Aimard, M Devic.   

Abstract

The information of 349 cases of multiple sclerosis, seen in a neurological department over a twenty-year period and followed up for a mean of nine years, was analysed by computerized data processing. The mean age at onset was 30.0 years for the remittent onset types (82 per cent cases) and 37.3 years for the progressive onset types (18 per cent cases). During the course of the disease the age of the 'pure relapse' stage was 29.2 years, of the relapse with sequelae stage 33.9 years and of the progressive phase 38.0 years. The interval between the first two relapses in the remittent-progressive type was important, the shorter the interval the sooner the progressive phase occurred. The relapses tended to increase in frequency before the progressive phase started. Using an actuarial graph, 50 per cent of cases could be expected to be moderately disabled (still ambulatory) in six years, and severely disabled (not ambulatory) in eighteen years and dead in thirty years. Combining a disability score and the duration of the disease prognostic factors could be studied. A late onset of the disease, a short interval between the first two relapses and the occurrence of the progressive phase were associated with a poor outcome. Sex of patient, the symptomatology of the initial relapses, and the constituents of the CSF had no prognostic value.

Entities:  

Mesh:

Year:  1980        PMID: 7397479     DOI: 10.1093/brain/103.2.281

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  89 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

2.  EDMUS, a European database for multiple sclerosis.

Authors:  C Confavreux; D A Compston; O R Hommes; W I McDonald; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

3.  24-month follow-up of multiple sclerosis patients treated with cyclophosphamide.

Authors:  E Millefiorini; M Di Giovanni; S Bernardi; M G Grasso; A Di Giampietro; D Gambi
Journal:  Ital J Neurol Sci       Date:  1990-12

4.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

Review 5.  Prognostic factors for multiple sclerosis: the importance of natural history studies.

Authors:  George C Ebers
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

Review 6.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 7.  [Dementia as a primary symptom in late onset multiple sclerosis. Case series and review of the literature].

Authors:  T Leyhe; C Laske; G Buchkremer; H Wormstall; H Wiendl
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 8.  Managing advanced multiple sclerosis.

Authors:  R W Teasell
Journal:  Can Fam Physician       Date:  1993-05       Impact factor: 3.275

9.  Multivariate analyses of factors associated with unemployment in people with multiple sclerosis.

Authors:  M Grønning; E Hannisdal; S I Mellgren
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-05       Impact factor: 10.154

10.  Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon.

Authors:  C Confavreux; C Chapuis-Cellier; P Arnaud; O Robert; G Aimard; M Devic
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.